Sugi Predict

Sugi Predict / Targets / DHCR24

DHCR24

Delta(24)-sterol reductase · Q15392 · DHCR24 on Sugi Atlas →

10,188 patent compounds predicted against DHCR24, 8,715 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL599029 SCHEMBL599029 0.77 11/20
SCHEMBL1237838 SCHEMBL1237838 0.77 11/20
SCHEMBL188329 SCHEMBL188329 0.74 11/20
SCHEMBL335520 SCHEMBL335520 0.74 11/20
SCHEMBL335521 SCHEMBL335521 0.74 11/20
SCHEMBL847506 SCHEMBL847506 0.74 11/20
SCHEMBL2396787 SCHEMBL2396787 0.72 11/20
SCHEMBL599030 SCHEMBL599030 0.60 11/20
SCHEMBL1237839 SCHEMBL1237839 0.60 11/20
SCHEMBL1446269 SCHEMBL1446269 0.55 11/20
SCHEMBL848376 SCHEMBL848376 0.54 11/20
SCHEMBL3122297 SCHEMBL3122297 0.52 11/20
Camphoratin I Camphoratin I (SCHEMBL1367776) 0.49 11/20
Camphoratin I Camphoratin I (SCHEMBL1367777) 0.49 11/20
SCHEMBL3122346 SCHEMBL3122346 0.48 11/20
SCHEMBL187737 SCHEMBL187737 0.77 10/20
SCHEMBL1957035 SCHEMBL1957035 0.77 10/20
SCHEMBL1446268 SCHEMBL1446268 0.72 10/20
SCHEMBL93966 SCHEMBL93966 0.65 10/20
SCHEMBL232490 SCHEMBL232490 0.65 10/20

Clinical trials — most relevant to DHCR24 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Single High Dose of Cholecalciferol on Serum Metabolites of Vitamin D PHASE4COMPLETED
Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism PHASE4COMPLETED
Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea PHASE3COMPLETED
Vitamin D Supplementation in Cirrhotic Patients PHASE2COMPLETED
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon PHASE2COMPLETED
Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome PHASE2COMPLETED
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children PHASE1/PHASE2UNKNOWN
Simvastatin Therapy in Smith-Lemli-Opitz Syndrome PHASE2COMPLETED
Vitamin D Intervention Trial in Healthy Chinese, Phase II PHASE1COMPLETED
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH PHASE1UNKNOWN
Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors PHASE1COMPLETED
Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer EARLY_PHASE1WITHDRAWN
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
Study of Smith-Lemli-Opitz Syndrome nanCOMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients nanNOT_YET_RECRUITING
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism nanCOMPLETED
Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism nanRECRUITING
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Effects of Vitamin D Dose and Genotype of the Binding Protein in Infants and Children nanCOMPLETED
A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome nanWITHDRAWN
Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia Patients nanCOMPLETED
Exome Sequencing in Autistic Spectrum Disorder nanCOMPLETED
Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients nanCOMPLETED
Is There Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome? nanUNKNOWN
DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements nanCOMPLETED
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome nanCOMPLETED
Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System nanCOMPLETED
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DHCR24 binder may also engage these)

ProteinNameSimilarity
Q8VCH6 — 1.000 Q8VCH6 →
Q5BQE6 — 1.000 Q5BQE6 →
Q60HC5 — 1.000 Q60HC5 →
O17397 — 0.983 O17397 →
Q90YK3 — 0.983 Q90YK3 →
P93472 — 0.980 P93472 →
Q39085 — 0.979 Q39085 →
Q0VGK4 — 0.975 Q0VGK4 →
AGPS Alkyldihydroxyacetonephosphate synthase, peroxisomal 0.973 landscape →
F1QF89 — 0.972 F1QF89 →
Q9CRY7 — 0.972 Q9CRY7 →
Q9EQR2 — 0.972 Q9EQR2 →
Q9V778 — 0.971 Q9V778 →
Q8N9F7 — 0.971 Q8N9F7 →
Q9HDX8 — 0.971 Q9HDX8 →
Q5R5P3 — 0.970 Q5R5P3 →
Q28DB0 — 0.969 Q28DB0 →
NAT10 RNA cytidine acetyltransferase 0.969 landscape →
P97275 — 0.969 P97275 →
Q6IV78 — 0.969 Q6IV78 →
Q6IV76 — 0.969 Q6IV76 →
A8E657 — 0.969 A8E657 →
Q96I59 — 0.969 Q96I59 →
Q9UDR5 — 0.969 Q9UDR5 →
Q6ZQY3 — 0.969 Q6ZQY3 →
Q7SGY1 — 0.969 Q7SGY1 →
Q68EH8 — 0.969 Q68EH8 →
Q9EPL9 — 0.968 Q9EPL9 →
Q16P90 — 0.968 Q16P90 →
Q9WVK4 — 0.968 Q9WVK4 →